356 related articles for article (PubMed ID: 18515402)
1. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
Advani A; Vaikkakara S; Gill MS; Arun CS; Pearce SH; Ball SG; James RA; Lennard TW; Bliss RD; Quinton R; Johnson SJ
J Clin Pathol; 2008 Aug; 61(8):939-44. PubMed ID: 18515402
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
3. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis.
Stojadinovic A; Brennan MF; Hoos A; Omeroglu A; Leung DH; Dudas ME; Nissan A; Cordon-Cardo C; Ghossein RA
Mod Pathol; 2003 Aug; 16(8):742-51. PubMed ID: 12920217
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant mitotane in adrenocortical carcinoma.
Dickstein G; Shechner C; Nativ O
N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
[No Abstract] [Full Text] [Related]
6. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
8. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
9. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.
Bilimoria KY; Shen WT; Elaraj D; Bentrem DJ; Winchester DJ; Kebebew E; Sturgeon C
Cancer; 2008 Dec; 113(11):3130-6. PubMed ID: 18973179
[TBL] [Abstract][Full Text] [Related]
10. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
Fassnacht M; Allolio B
Clin Endocrinol (Oxf); 2010 Nov; 73(5):561-5. PubMed ID: 20738315
[TBL] [Abstract][Full Text] [Related]
11. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant mitotane in adrenocortical carcinoma.
Lee JE
N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
[No Abstract] [Full Text] [Related]
13. Adrenal incidentalomas: risk of adrenocortical carcinoma and clinical outcomes.
O'Neill CJ; Spence A; Logan B; Suliburk JW; Soon PS; Learoyd DL; Sidhu SB; Sywak MS
J Surg Oncol; 2010 Oct; 102(5):450-3. PubMed ID: 20734420
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive treatment of adrenocortical carcinoma.
Terzolo M; Berruti A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience.
Tritos NA; Cushing GW; Heatley G; Libertino JA
Am Surg; 2000 Jan; 66(1):73-9. PubMed ID: 10651352
[TBL] [Abstract][Full Text] [Related]
16. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma.
Reibetanz J; Jurowich C; Erdogan I; Nies C; Rayes N; Dralle H; Behrend M; Allolio B; Fassnacht M;
Ann Surg; 2012 Feb; 255(2):363-9. PubMed ID: 22143204
[TBL] [Abstract][Full Text] [Related]
17. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
Demeure MJ; Somberg LB
Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134
[TBL] [Abstract][Full Text] [Related]
18. Contemporary management of adrenocortical carcinoma.
Zini L; Porpiglia F; Fassnacht M
Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant mitotane in adrenocortical carcinoma.
Bertherat J; Coste J; Bertagna X
N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
[No Abstract] [Full Text] [Related]
20. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
